TriSalus Life Sciences (NASDAQ:TLSI) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of TriSalus Life Sciences (NASDAQ:TLSI) from a hold rating to a sell rating in a research note published on Saturday.

TLSI has been the topic of a number of other reports. Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a report on Friday, August 7th. Lake Street Capital reduced their target price on TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, TriSalus Life Sciences has a consensus rating of “Hold” and an average target price of $7.50.

TriSalus Life Sciences Price Performance

NASDAQ:TLSI opened at $5.27 on Friday. The company has a market cap of $324.53 million, a PE ratio of -4.05 and a beta of 0.43. TriSalus Life Sciences has a twelve month low of $2.20 and a twelve month high of $7.95. The company has a current ratio of 5.35, a quick ratio of 4.97 and a debt-to-equity ratio of 5.05. The company’s 50 day moving average is $4.43 and its two-hundred day moving average is $4.30.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.16). The company had revenue of $11.41 million for the quarter, compared to analyst estimates of $10.27 million.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in TLSI. Cura Wealth Advisors LLC acquired a new position in TriSalus Life Sciences during the second quarter valued at $36,000. JPMorgan Chase & Co. grew its position in TriSalus Life Sciences by 35,804.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock worth $41,000 after purchasing an additional 7,519 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in TriSalus Life Sciences during the 2nd quarter worth about $47,000. Invesco Ltd. acquired a new position in shares of TriSalus Life Sciences in the 4th quarter valued at about $72,000. Finally, Abel Hall LLC purchased a new stake in shares of TriSalus Life Sciences in the fourth quarter worth about $73,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.